Inductive Bio Raises $25M Series A to Advance AI Models for Small Molecule Drug Discovery

Inductive Bio is developing a collaborative AI platform designed to accelerate compound optimization in small-molecule drug discovery.

Inductive Bio Raises $25M Series A to Advance AI Models for Small Molecule Drug Discovery
Source: Inductive Bio

Company Name: Inductive Bio
Location: New York, NY
Industry: AI / Drug Discovery

Funding Details:

  • Amount: $25M (Series A)
  • Investors:
    • Lead: Obvious Ventures
    • Participants: Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, Amino Collective
    • Angels: Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, Jakob Uszkoreit

Purpose of Investment:

  • Expand AI model R&D
  • Grow its pre-competitive data consortium

Leadership:

Product:
Inductive Bio is developing a collaborative AI platform designed to accelerate compound optimization in small-molecule drug discovery. By building advanced ML models around ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) and forming a pre-competitive data consortium, the company enables pharma scientists to optimize hits into viable drug candidates faster and with better pharmacological profiles.

About Company:
In a recent collaboration with Nested Therapeutics, published in ACS Medicinal Chemistry Letters, Inductive Bio’s platform was used to overcome permeability and metabolic stability challenges. The result: nomination of a drug development candidate with strong potency and cross-species pharmacokinetics, underscoring the real-world impact of Inductive Bio’s AI-first approach to medicinal chemistry.

Read next